- •Diabetic Retinopathy
- •Preface
- •Acknowledgments
- •Contents
- •Contributors
- •Pathophysiology of Diabetic Retinopathy
- •1.1 Retinal Anatomy
- •1.1.1 History
- •1.1.2 Anatomy
- •1.1.3 Microanatomy of the Retina Neurons
- •1.1.4 Intercellular Spaces
- •1.1.5 Internal Limiting Membrane
- •1.1.6 Circulation
- •1.1.7 Arteries
- •1.1.8 Veins
- •1.1.9 Capillaries
- •1.2 Hemodynamics, Macular Edema, and Starling’s Law
- •1.3 Biochemical Basis for Diabetic Retinopathy
- •1.3.1 Increased Polyol Pathway Flux
- •1.3.2 Advanced Glycation End Products (AGEs)
- •1.3.3 Activation of Protein Kinase C (PKC)
- •1.3.4 Increased Hexosamine Pathway Flux
- •1.4 Macular Edema
- •1.5 Development of Proliferative Diabetic Retinopathy
- •1.6 Summary of Key Points
- •1.7 Future Directions
- •References
- •Genetics and Diabetic Retinopathy
- •2.1 Background for Clinical Genetics
- •2.2 The Role of Polymorphisms in Genetic Studies
- •2.3 Types of Genetic Study Design
- •2.4 Studies of the Genetics of Diabetic Retinopathy
- •2.4.1 Clinical Studies
- •2.4.2 Molecular Genetic Studies
- •2.4.3 EPO Promoter
- •2.4.4 Aldose Reductase Gene
- •2.4.5 VEGF Gene
- •2.5 Genes in or Near the HLA Locus
- •2.6 Receptor for Advanced Glycation End Products (RAGE) Genes
- •2.7 Endothelial NOS2 and NOS3 Genes
- •2.9 Solute Carrier Family 2 (Facilitated Glucose Transporter), Member 1 Gene (SLC2A1)
- •2.11 Potential Value of Identifying Genetic Associations with Diabetic Retinopathy
- •2.12 Summary of Key Points
- •2.13 Future Directions
- •Glossary
- •References
- •Epidemiology of Diabetic Retinopathy
- •3.1 Introduction and Definitions
- •3.2 Epidemiology of Diabetes Mellitus
- •3.3 Factors Influencing the Prevalence of Diabetes Mellitus
- •3.4 Epidemiology of Diabetic Retinopathy
- •3.5 Diabetes and Visual Loss
- •3.6 Prevalence and Incidence of Diabetic Retinopathy
- •3.7 By Diabetes Type
- •3.8 By Insulin Use
- •3.10 By Duration of Diabetes Mellitus
- •3.11 By Ethnicity
- •3.12 Gender
- •3.13 Age at Onset of Diabetes
- •3.14 Socioeconomic Status and Educational Level
- •3.15 Family History of Diabetes
- •3.16 Changes Over Time
- •3.17 Epidemiology of Diabetic Macular Edema (DME)
- •3.18 Epidemiology of Proliferative Diabetic Retinopathy (PDR)
- •3.19 Socioeconomic Impact of Diabetes
- •3.20 Socioeconomic Impact of Diabetic Retinopathy
- •3.21 Summary of Key Points
- •3.22 Future Directions
- •References
- •Systemic and Ocular Factors Influencing Diabetic Retinopathy
- •4.1 Introduction
- •4.2 Systemic Factors
- •4.2.1 Glycemic Control
- •4.2.1.1 Type 1 Diabetes Mellitus
- •4.2.1.2 Type 2 Diabetes Mellitus
- •4.2.1.3 Rapidity of Improvement in Glycemic Control
- •4.2.2 Glycemic Variability
- •4.2.3 Insulin Use in Type 2 Diabetes
- •4.2.5 Blood Pressure
- •4.2.6 Serum Lipids
- •4.2.7 Anemia
- •4.2.8 Nephropathy
- •4.2.9 Pregnancy
- •4.2.10 Other Systemic Factors
- •4.2.11 Influence on Visual Loss
- •4.3 Effects of Systemic Drugs
- •4.3.1 Diuretics
- •4.3.3 Aldose Reductase Inhibitors
- •4.3.4 Drugs That Target Platelets
- •4.3.5 Statins
- •4.3.6 Protein Kinase C Inhibitors
- •4.3.7 Thiazolidinediones (Glitazones)
- •4.3.8 Miscellaneous Drugs
- •4.4 Ocular Factors Influencing Diabetic Retinopathy
- •4.6 Economic Consequences
- •4.7 Summary of Key Points
- •4.8 Future Directions
- •References
- •Defining Diabetic Retinopathy Severity
- •5.1 Summary of Key Points
- •5.2 Future Directions
- •5.3 Practice Exercises
- •References
- •6.1 Optical Coherence Tomography (OCT)
- •6.2 Heidelberg Retinal Tomograph (HRT)
- •6.3 Retinal Thickness Analyzer (RTA)
- •6.4 Microperimetry
- •6.5 Color Fundus Photography
- •6.6 Fluorescein Angiography
- •6.7 Ultrasonography
- •6.8 Multifocal ERG
- •6.9 Miscellaneous Modalities
- •6.10 Summary of Key Points
- •6.11 Future Directions
- •6.12 Practice Exercises
- •References
- •Diabetic Macular Edema
- •7.1 Epidemiology and Risk Factors
- •7.2 Pathophysiology and Pathoanatomy
- •7.2.1 Anatomy
- •7.3 Physiology
- •7.4 Clinical Definitions
- •7.5 Focal and Diffuse Diabetic Macular Edema
- •7.6 Subclinical Diabetic Macular Edema
- •7.7 Refractory Diabetic Macular Edema
- •7.8 Regressed Diabetic Macular Edema
- •7.9 Recurrent Diabetic Macular Edema
- •7.10 Methods of Detection of Diabetic Macular Edema
- •7.11 Case Report 1
- •7.12 Case Report 2
- •7.13 Other Ancillary Studies in Diabetic Macular Edema
- •7.14 Natural History
- •7.15 Treatments
- •7.15.1 Metabolic Control and Effects of Drugs
- •7.16 Focal/Grid Laser Photocoagulation
- •7.16.1 ETDRS Treatment of CSME
- •7.17 Evolution in Focal/Grid Laser Treatment Since the ETDRS
- •7.18 Macular Thickness Outcomes After Focal/Grid Photocoagulation
- •7.19 Resolution of Lipid Exudates After Focal/Grid Laser Photocoagulation
- •7.20 Inconsistency in Defining Refractory Diabetic Macular Edema
- •7.21 Alternative Forms of Laser Treatment for Diabetic Macular Edema
- •7.22 Peribulbar Triamcinolone Injection
- •7.23 Intravitreal Triamcinolone Injection
- •7.24 Intravitreal Dexamethasone Delivery System
- •7.27 Combined Intravitreal and Peribulbar Triamcinolone and Focal Laser Therapy
- •7.28 Vitrectomy
- •7.29 Supplemental Oxygen and Hyperbaric Oxygenation
- •7.30 Resection of Subfoveal Hard Exudates
- •7.31 Subclinical Diabetic Macular Edema
- •7.32 Cases with Simultaneous Indications for Focal and Scatter Laser Photocoagulation
- •7.34 Factors Influencing Treatment of Diabetic Macular Edema
- •7.35 Sequence of Therapy
- •7.36 Interaction of Cataract Surgery and Diabetic Macular Edema
- •7.37 Summary of Key Points
- •7.38 Future Directions
- •References
- •Diabetic Macular Ischemia
- •8.1 Introduction
- •8.2 Pathogenesis, Anatomy, and Physiology
- •8.3 Natural History
- •8.4 Clinical Evaluation
- •8.5 Clinical Significance of Diabetic Macular Ischemia
- •8.6 Controversies and Conundrums
- •8.7 Summary of Key Points
- •8.8 Future Directions
- •References
- •Treatment of Proliferative Diabetic Retinopathy
- •9.1 Introduction
- •9.2 Laser Photocoagulation
- •9.2.1 Indications
- •9.2.2 PRP Technique
- •9.2.3 Complications
- •9.2.4 Outcome
- •9.3 Intraocular Pharmacological Therapy
- •9.4 Vitreoretinal Surgery
- •9.4.1 Indications
- •9.4.2 Preoperative Management
- •9.4.3 Instrumentation
- •9.4.4 Techniques
- •9.4.5 Postoperative Management
- •9.4.6 Complications
- •9.4.7 General Outcome
- •9.5 Follow-Up Considerations in PDR
- •9.6.1 Cataract and PDR
- •9.6.2 Dense Vitreous Hemorrhage and Untreated PDR
- •9.6.3 Untreated PDR with Diabetic Macular Edema
- •9.6.4 PDR with Severe Fibrovascular Proliferation/Traction Retinal Detachment
- •9.6.5 PDR with Neovascular Glaucoma
- •9.6.6 Conditions Altering the Clinical Course of PDR
- •9.7 Summary of Key Points
- •9.8 Future Directions
- •References
- •Cataract Surgery and Diabetic Retinopathy
- •10.1 Scope of the Problem of Diabetic Retinopathy Concomitant with Surgical Cataract
- •10.2 Visual Outcomes After Cataract Surgery in Patients with Diabetic Retinopathy
- •10.3 Postoperative Course and Special Considerations After Cataract Surgery in Patients with Diabetic Retinopathy
- •10.4 The Influence of Cataract Surgery on Diabetic Retinopathy
- •10.5 The Role of Ancillary Testing in Managing Cataract Surgery in Eyes with Diabetic Retinopathy
- •10.6 Candidate Risk and Protective Factors for Diabetic Macular Edema Induction or Exacerbation Following Cataract Surgery and Suggested Management Actions
- •10.7 The Problem of Adherence to Preferred Practice Guidelines
- •10.8 Management of the Diabetic Eye Without Macular Edema About to Undergo Cataract Surgery
- •10.9 Treatment of Diabetic Macular Edema Detected Before Cataract Surgery When the Macular View Is Clear
- •10.10 Management When Cataract Sufficient to Obscure the Macular View and DME Coexist or When Refractory DME and Cataract Coexist
- •10.11 Patients with Simultaneous Indications for Panretinal Photocoagulation and Cataract Surgery
- •10.12 Management of Cataract in Patients with Diabetic Retinopathy Undergoing Vitrectomy
- •10.13 Influence of Vitrectomy Surgery on Cataract Formation
- •10.15 Postoperative Endophthalmitis in Patients with Diabetic Retinopathy
- •10.16 Summary of Key Points
- •10.17 Future Directions
- •References
- •The Relationship of Diabetic Retinopathy and Glaucoma
- •11.1 Interaction of Diabetes and Glaucoma
- •11.2 Iris and Angle Neovascularization Pathoanatomy and Pathophysiology
- •11.3 Epidemiology
- •11.4 Clinical Detection
- •11.5 Classification
- •11.6 Risk Factors for Iris Neovascularization
- •11.7 Entry Site Neovascularization After Pars Plana Vitrectomy
- •11.8 Anterior Hyaloidal Fibrovascular Proliferation
- •11.9 Treatments for Iris Neovascularization
- •11.10 Modifiers of Behavior of Iris Neovascularization
- •11.11 Management of Neovascular Glaucoma
- •11.12 Summary of Key Points
- •11.13 Future Directions
- •References
- •The Cornea in Diabetes Mellitus
- •12.1 Introduction
- •12.2 Pathophysiology
- •12.3 Anatomy and Morphological Changes
- •12.4 Clinical Manifestations
- •12.5 Ocular Surgery
- •12.6 Treatment of Corneal Disease in Diabetes Mellitus
- •12.7 Conclusion
- •12.8 Summary of Key Points
- •12.9 Future Directions
- •References
- •Optic Nerve Disease in Diabetes Mellitus
- •13.1 Relevant Normal Optic Nerve Anatomy and Physiology
- •13.2 The Effect of Diabetes on the Optic Nerve
- •13.3 Nonarteritic Anterior Ischemic Optic Neuropathy and Diabetes
- •13.4 Diabetic Papillopathy
- •13.5 Disk Edema Associated with Vitreous Traction
- •13.6 Superior Segmental Optic Hypoplasia (Topless Optic Disk Syndrome)
- •13.7 Wolfram Syndrome
- •13.8 Summary of Key Points
- •13.9 Future Directions
- •References
- •Screening for Diabetic Retinopathy
- •14.1 Introduction
- •14.2 Who Does Not Need to Be Screened
- •14.5 Screening with Dilated Ophthalmoscopy by Ophthalmic Technicians or Optometrists
- •14.6 Screening with Dilated Ophthalmoscopy by Ophthalmologists
- •14.7 Screening with Dilated Ophthalmoscopy by Retina Specialists
- •14.8 Photographic Screening
- •14.9 Nonmydriatic Photography
- •14.10 Mydriatic Photography
- •14.11 Risk Factors for Ungradable Photographs
- •14.12 Number of Photographic Fields
- •14.13 Criteria for Referral
- •14.14 Obstacles to the Use of Teleophthalmic Screening Methods
- •14.15 Combination Methods of Screening
- •14.16 Case Yield Rates
- •14.17 Compliance with Recommendation to Be Seen by an Ophthalmologist
- •14.18 Intravenous Fluorescein Angiography and Oral Fluorescein Angioscopy
- •14.19 Automated Fundus Image Interpretation
- •14.20 Subgroups Needing Enhanced Screening Efforts
- •14.21 Screening in Pregnancy
- •14.22 Economic Considerations
- •14.23 Comparisons of the Screening Methods
- •14.24 Accountability of Screening Programs
- •14.25 Summary of Key Points
- •14.26 Future Directions
- •References
- •Practical Concerns with Ethical Dimensions in the Management of Diabetic Retinopathy
- •15.1 Incorporating Ancillary Testing in the Management of Patients with Diabetic Retinopathy
- •15.2.1 Case 1
- •15.2.2 Case 2
- •15.4 Working in a Managed Care Environment (Capitation)
- •15.5 Interactions with Medical Industry
- •15.7 Comanagement of Patients
- •15.9 Summary of Key Points
- •15.10 Future Directions
- •References
- •Clinical Examples in Managing Diabetic Retinopathy
- •16.1.1 Discussion
- •16.2 Case 2: Bilateral Proliferative Diabetic Retinopathy with Acute Vitreous Hemorrhage in One Eye and a Chronic Traction Retinal Detachment in the Other Eye
- •16.2.1 Discussion
- •16.2.2 Opinion 1
- •16.2.3 Opinion 2
- •16.2.4 Opinion 3
- •16.3 Case 3: Sight Threatening Diabetic Retinopathy in a Patient with Concomitant Medical and Socioeconomic Problems
- •16.3.1 Discussion
- •16.4 Case 4: Asymptomatic Retinal Detachment Following Vitrectomy in a Patient Who Has Had Panretinal Laser Photocoagulation
- •16.4.1 Discussion
- •16.5 Case 5: Management of Progressive Vitreous Hemorrhage Following Scatter Photocoagulation for Proliferative Diabetic Retinopathy
- •16.5.1 Discussion
- •16.6.1 Discussion
- •16.7 Case 7: Proliferative Diabetic Retinopathy with Macular Traction and Ischemia
- •16.7.1 Discussion
- •16.8 Case 8: What Is Maximal Focal/Grid Laser Photocoagulation for Diabetic Macular Edema?
- •16.8.1 Definition of the Problem
- •16.8.2 Discussion
- •16.9 Case 9: What Independent Information Does Macular Perfusion Add to Patient Management in Diabetic Retinopathy?
- •16.9.1 Discussion
- •16.10 Case 10: Macular Edema Following Panretinal Photocoagulation for Proliferative Diabetic Retinopathy
- •16.10.1 Discussion
- •16.11 Case 11: Diabetic Macular Edema with a Subfoveal Scar
- •16.11.1 Discussion
- •16.12.1 Definition of the Problem
- •16.12.2 Discussion
- •16.13.1 Definition of the Problem
- •16.13.2 Discussion
- •16.14 Case 14: How Is Diabetic Macular Ischemia Related to Visual Acuity?
- •16.14.1 Definition of the Problem
- •16.14.2 Discussion
- •References
- •Subject Index
Chapter 13
Optic Nerve Disease in Diabetes Mellitus
David J. Browning
13.1Relevant Normal Optic Nerve Anatomy and Physiology
The vascular supply of the optic nerve depends on the stratum of the optic nerve head under consideration. The optic nerve head is divided into four strata
– superficial nerve fiber layer, prelaminar layer, laminar layer, and retrolaminar layer. Fine retinal arterioles arising in the peripapillary retina and derived from the central retinal artery supply the superficial nerve fiber layer of the optic nerve; there is no posterior ciliary contribution.1The prelaminar and laminar optic nerve derive their blood supply primarily from the paraoptic short posterior ciliary arteries and the circumferential vessels of the circle of Zinn-Haller (Fig. 13.1).2–5 The circle of Zinn-Haller, where it exists, is an intermediary between the posterior ciliary arteries and the anterior optic nerve small vessels.1,6 There may be smaller and inconsistent
contributions from peripapillary choroidal arteries.1,2,6,7 Although the circle of Zinn-Haller is
present in the peripapillary sclera in most eyes studied by plastic cast studies in cadaver eyes, there is some controversy about whether the circle is functional and whether it serves as an intermediary between the short posterior ciliary arteries and the optic disk blood supply.1,8 In vivo, the perfusion of the circle of Zinn-Haller can only be seen in highly myopic eyes with peripapillary crescents by using ICG angiography.9 In such eyes, the circle of Zinn-
D.J. Browning (*)
Charlotte Eye Ear Nose & Throat Associates, Charlotte, NC 28210, USA
e-mail: dbrowning@ceenta.com
Haller has been found to be incomplete, but one cannot generalize to the case of normal eyes. The mesh of capillaries in the anterior optic nerve has spacing of 30–50 mm to 50–85 mm and connects with the capillary mesh of the laminar portion of the optic
disk and the overlying superficial nerve fiber layer.1,2,10 The capillaries themselves have a luminal
diameter of 7–10 mm.2 Electron microscopy shows tight junctions between capillary endothelial cells of the optic nerve, thus a blood–optic nerve barrier exists in analogy to the blood–retina barrier.11,12 The retrolaminar optic nerve head is supplied both by the short posterior ciliary arteries via branches to the circle of Zinn-Haller and thence to pial arteries and by branches of the central retinal artery.13
The intravascular pressure of the short posterior ciliary artery branches to the anterior optic nerve has been deduced to be somewhat lower than the intravascular pressure of branches of the central retinal artery based on fluorescein angiograms of primates performed with elevated, controlled intraocular pressure in an experimental model suggesting vulnerability of the optic nerve head should perfusion pressure fall.3
The optic nerve shares the property of autoregulation with the retina.12,14–16 Systemic controls on
optic nerve blood flow are absent or minor, but local factors mediated by nitric oxide, endothelin, prostaglandins, and the renin–angiotensin system are important.17 The ocular perfusion pressure (OPP) is defined as follows:
OPP = mean rterial blood pressure – intraocular pressure
=[diastolic blood pressure + 1/3 (systolic
blood pressure – diastolic blood pressure)]
– intraocular pressure 14,18
D.J. Browning (ed.), Diabetic Retinopathy, DOI 10.1007/978-0-387-85900-2_13, |
357 |
Springer ScienceþBusiness Media, LLC 2010 |
|
358 |
D.J. Browning |
|
|
Fig. 13.1 Schematic of the vascular supply of the anterior optic nerve. Contributions from the paraoptic short posterior ciliary arteries (PCA) and the choroid are important, whereas contributions from peripapillary retinal arterioles (RETINA) and perineural meningeal arterioles (MENING) are inconsistent or questionable (signified by ?). CRV = central retinal vein. Reprinted with permission from Henkind2
In most, but not all, humans, the optic nerve vascular response to an increase in perfusion pressure of up to 45 mm Hg is vasoconstriction such that optic nerve head blood flow tends to remain constant. Likewise, with a fall in perfusion pressure by raising intraocular pressure, the optic disk arterioles tend to dilate and protect optic disk oxygen tension.12 Some persons seem to have a reduced optic nerve autoregulatory capacity and may be more susceptible to ischemia of the optic nerve. Although both arterial blood pressure and intraocular pressure affect the ocular perfusion pressure, it is not known if changes induced by the two factors produce equivalent responses.14
13.2The Effect of Diabetes on the Optic Nerve
The retinal nerve fiber layer thickness is reduced in diabetes mellitus compared to control eyes with increasing atrophy as retinopathy severity
increases. Thus diabetes can be a source of overestimation of glaucomatous optic neuropathy when scanning laser polarimetry is used to monitor progression of glaucomatous optic atrophy.19
The neuroretinal rim area of the optic nerve has been studied longitudinally in a subset of photographs taken as part of the Wisconsin Study of Diabetic Retinopathy.20 In younger onset and older onset diabetics, the neuroretinal rim area increased over a 4-year period. In addition, the neuroretinal rim area was larger in eyes with more severe retinopathy at baseline. It is possible that diabetes is associated with subclinical optic disk swelling in general.
Although rare, optociliary shunt vessels can arise de novo in diabetic retinopathy, perhaps signifying a relative venous obstruction at the lamina cribrosa. The more common causes of optociliary shunt vessels are spheno-orbital meningiomas, central retinal vein occlusions, primary open angle glaucoma, papilledema, optic nerve glioma, optic disk drusen, arachnoid cyst of the
13 Optic Nerve Disease in Diabetes Mellitus |
359 |
|
|
optic nerve, phakomatoses, and rarely congenital abnormality.21
13.3Nonarteritic Anterior Ischemic Optic Neuropathy and Diabetes
Nonarteritic anterior ischemic optic neuropathy (NAION) is generally considered to occur as a response to hypoperfusion of the branches of the
posterior ciliary arteries that supply the optic disk.22–25 An alternative hypothesis – that the pri-
mary disorder is relative central venous occlusion – has been advanced but not embraced.26 The annual
incidence of NAION is 2.3–10.3 per 100,000 persons.24,25 Although more common in the elderly
with the median age of affected patients being 62 years, it can strike the young (range 12–92 years).27 Visual loss is most frequently noted upon awakening from sleep suggesting that nocturnal hypotension may have a role in the condition.28 Hypoxia induces axoplasmic flow stasis, neural swelling, and dilated capillaries on the surface of the disk with peripapillary splinter hemorrhages more prominent
in patients with diabetes than in those without (Fig. 13.2).29,30 Because the space through which
the optic nerve passes is typically restricted as reflected in a small optic disk cup, the axonal swelling is thought to compress the capillaries further, in turn exacerbating ischemia and producing a vicious spiral ending in tissue infarction.30–32 Diabetes mellitus is a risk factor for NAION, and others include hypertension, nocturnal or post-surgical
hypotension, older age, smoking, sleep apnea, and anemia.23,33–42 Cataract surgery may be a minor
risk factor.43 The role of thrombophilic factors has been inconsistent. Although thrombophilic risk factors have been absent in most studies, one study reported elevated levels of lipoprotein (a), von Willebrand antigen, factor V Leiden, cholesterol, and fibrinogen in patients with NAION.44–46
Central scotomata are present in 55.3% and 36.2% of eyes with the I-2e and V-4e targets, respectively.47 Inferonasal sector loss is the most common sectoral defect (22.4%).47 An inferior altitudinal field defect is seen in 8.0% of eyes.47 Many other visual field defects can be seen and in 6.4% of eyes no field defect is present.47 The sector
of optic disk edema and the location of the visual field defects correlate early in the condition.30 As the edema resolves, however, the correlation vanishes.25 At a later stage, the correlation of sectoral optic pallor and the observed visual field defects is also poor.30 A relative afferent pupillary defect is usually present.33
Before visual dysfunction occurs, there may be asymptomatic optic disk edema, which has been
termed incipient nonarteritic anterior ischemic optic neuropathy (Fig. 13.2).22,48,49 Twenty five to
31% of cases of incipient NAION resolve with the
rest progressing to NAION and some visual loss involving acuity or field or both.22,50
Previous fellow eye involvement at baseline is seen in 21.1% of patients and new fellow eye involvement occurs in 14.7% of patients over 5 years of follow-up with half the cases occurring in the first year after first eye involvement.23 Presence of diabetes mellitus
increases the incidence of fellow eye involvement.23 Recurrences in the same eye are uncommon.51,52
NAION in patients with diabetes has some differences compared to the condition in nondiabetics. Diabetic patients with NAION have a higher prevalence of hypertension, ischemic heart disease, transient ischemic attacks, and second eye involve-
ment than patients who have NAION without diabetes.23,53 Time to resolution of disk edema is longer
in patients with diabetes than in patients without diabetes.30,53 Median time to second eye involvement is shorter in patients with diabetes than in patients without diabetes.53 In some respects, diabetic and nondiabetic patients are similar. The fluorescein angiographic findings are the same. The optic disk shows fluorescein leakage of swollen sectors in both groups of patients.30,53 Both groups of patients have small cup-to-disk ratios. At 6 months after diagnosis, the visual acuity and visual field outcomes are similar in diabetic and nondiabetic groups.53
Subsequent optic disk pallor after the acute
hyperemia of NAION occurs approximately 6–12 weeks later.30,33 Atrophic cupping of the optic nerve
after NAION is not seen, in contrast to arteritic ION, where subsequent optic cupping can be part of the clinical picture.33
Although controversial, some have linked the use of phosphodiesterase-5 inhibitors for the treatment of erectile dysfunction and the development of
360 |
D.J. Browning |
|
|
e
f
Fig. 13.2 Example of incipient nonarteritic ischemic optic neuropathy. The patient was a 65-year-old man with type 2, insulin-requiring diabetes mellitus, hypertension, and sleep apnea. He had had uneventful cataract surgery in the right eye 8 months earlier and in the left eye 3 months earlier. He complained of acute onset of painless, blurred vision of the left eye for 3 weeks and had no complaints with regard to the right eye. Best corrected visual acuity was 20/20 in each
eye. Both eyes had optic disk edema, more prominent on the left than the right (a and b); on the right only the superior pole of the nerve was involved. Fluorescein angiography showed late disk hyperfluorescence bilaterally, more prominent on the left than the right (c and d). The visual field was normal on the right (mean defect –1.94 db) and showed some patchy superior scotomata on the left (mean defect –3.42 db) (e and f)
